Beta blocker efficacy in treating palpitations
Pro Research Analysisby 
Searched over 200M research papers
Beta Blockers for Palpitations: Efficacy in Arrhythmia and Symptom Control
Beta blockers are widely used to manage palpitations, especially when these are caused by arrhythmias such as atrial fibrillation or frequent ventricular ectopic beats. Studies show that beta blockers help by slowing the heart rate and reducing the frequency of irregular heartbeats, which can directly decrease the sensation of palpitations and improve cardiac function parameters compared to non-beta blocker treatments 13.
Beta Blockers in Specific Patient Populations
Atrial Fibrillation and Ventricular Ectopy
In patients with atrial fibrillation, beta blockers have been shown to lower hospital readmission rates and improve heart function more effectively than non-beta blocker medications . For those with frequent ventricular ectopic beats, including patients with systemic sclerosis, beta blockers significantly reduced the number of ectopic beats and episodes of non-sustained ventricular tachycardia, with a mean reduction of nearly 75% in ectopic beats. Importantly, this benefit was achieved without worsening other complications such as digital ulcers or Raynaud’s phenomenon .
Palpitations in Anxiety
Beta blockers are also used off-label to treat palpitations associated with acute anxiety or panic. They are effective in reducing physical symptoms like tachycardia and palpitations, but do not address the psychological symptoms of anxiety such as fear or avoidance .
Palpitations During Pregnancy
Beta blockers are considered a primary treatment for palpitations due to supraventricular or ventricular ectopy in pregnancy. However, their use has been associated with an increased risk of small for gestational age infants and a tendency toward higher rates of pregnancy-induced hypertension. There was no significant difference in other pregnancy outcomes such as preterm birth or stillbirth .
Gender Differences in Beta Blocker Use and Outcomes
Among patients presenting with palpitations, women are slightly more likely than men to be prescribed beta blockers and referred for cardiac rhythm monitoring. Women also have a lower risk of hospitalization for arrhythmias and lower all-cause mortality at one year compared to men, suggesting a favorable prognosis in this group .
Conclusion
Beta blockers are effective in reducing palpitations, especially when these are due to arrhythmias like atrial fibrillation or frequent ventricular ectopic beats. They are also helpful for the physical symptoms of palpitations in anxiety. However, caution is needed in special populations such as pregnant women, where potential risks must be weighed. Overall, beta blockers remain a key option for managing palpitations, with evidence supporting their efficacy and safety in most patient groups 1234+1 MORE.
Sources and full results
Most relevant research papers on this topic
A PROSPECTIVE OBSERVATIONAL STUDY ON TREATMENT OF ATRIAL FIBRILLATION WITH OR WITHOUT BETA-BLOCKERS.
Beta blockers significantly reduce hospital readmissions and improve cardiac function in atrial fibrillation patients compared to non-beta blocker treatments.
AB0699 Beta-Blockers Control Frequent Ventricular Ectopic Beats in Systemic Sclerosis: A Monocentric Study
Beta-blockers effectively reduce frequent ventricular ectopic beats in systemic sclerosis patients, potentially reducing sudden cardiac death risk.
Abstract 15005: Gender Differences in the Evaluation and Clinic Outcomes of Patients With Palpitations
Women with palpitations are more likely to receive beta-blockers and undergo cardiac rhythm monitoring, leading to a better clinical prognosis and lower risk of hospitalization for arrhythmias and death at one year.
Beta-Blockers and Their Current Role in Maternal and Neonatal Health: A Narrative Review of the Literature
Beta-blockers are used to treat cardiovascular conditions in pregnancy, but their safety and efficacy in fetal and neonatal health require further studies.
Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy.
Flecainide combined with beta-blockers is a safe and effective treatment for persistent symptomatic ventricular arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy.
DOI